Navigation Links
Provectus Biopharmaceuticals, Inc. Announces Extension of Rights Offering
Date:2/10/2017

KNOXVILLE, Tenn., Feb. 10, 2017 /PRNewswire/ -- Provectus Biopharmaceuticals, Inc. (OTCQB: PVCT, www.provectusbio.com) ("Provectus" or the "Company"), a clinical-stage oncology and dermatology biopharmaceutical company, today announced that it has extended the expiration date of its rights offering to Friday, March 3, 2017 at 5:00 p.m. Eastern Time. All other terms and conditions of the rights offering remain unchanged. 

The units being offered pursuant to the rights offering are being offered under the Company's effective registration statement on Form S-1 (No. 333-213986) by means of a prospectus, as supplemented from time to time, which has been filed with the Securities and Exchange Commission ("SEC") and is available on the website of the SEC at http://www.sec.gov. Electronic copies of the prospectus and prospectus supplements also may be obtained from Maxim Group LLC, 405 Lexington Avenue, 2nd Floor, New York, NY 10174, at 212-895-3745.  Before you invest, you should read the prospectus, as supplemented from time to time, and other documents Provectus has filed or will file with the SEC for more complete information about Provectus and the rights offering.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.

About Provectus

Provectus is a clinical-stage biopharmaceutical company developing new therapies for the treatment of solid tumor cancers and dermatologic diseases. Provectus' investigational oncology drug, PV-10, is an oncolytic immunotherapy currently enrolling patients in Phase 3 clinical trials for metastatic melanoma. The Company has received orphan drug designations from the FDA for its melanoma and hepatocellular carcinoma indications. PH-10, its topical investigational drug, has completed Phase 2 clinical trials as a treatment for atopic dermatitis and psoriasis. Information about these and the Company's other clinical trials can be found at the NIH registry, www.clinicaltrials.gov. For additional information about Provectus, please visit the Company's website at www.provectusbio.com or contact Allison + Partners.

FORWARD-LOOKING STATEMENTS: This release contains "forward-looking statements" as defined under U.S. federal securities laws. These statements reflect management's current knowledge, assumptions, beliefs, estimates, and expectations and express management's current views of future performance, results, and trends and may be identified by their use of terms such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "plan," "predict," "project," "will," and other similar terms. Forward-looking statements are subject to a number of risks and uncertainties that could cause our actual results to materially differ from those described in the forward-looking statements. Readers should not place undue reliance on forward-looking statements. Such statements are made as of the date hereof, and we undertake no obligation to update such statements after this date.

Risks and uncertainties that could cause our actual results to materially differ from those described in forward-looking statements include those discussed in our filings with the Securities and Exchange Commission (including those described in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2015, as supplemented by those described in Part II, Item 1A of our Quarterly Report on Form 10-Q for the quarter ended September 30, 2016) and the following:

  • Provectus' potential receipt of sales from PV-10 and PH-10, transaction fees, licensing and royalty payments; payments in connection with the Company's liquidation, dissolution or winding up, or any sale, lease, conveyance or other disposition of any intellectual property relating to PV-10 or PH-10.
  • our ability to raise additional capital if we determine to commercialize PV-10 and/or PH-10 on our own;
  • our ability to raise capital through the rights offering; and
  • whether our securities remain listed on the NYSE MKT.

Contact:
Provectus Biopharmaceuticals, Inc.
Timothy C. Scott, President
Phone: 866-594-5999

Allison + Partners
Tom Smith, Managing Director –
Investor Relations
Phone: 646-428-0653

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/provectus-biopharmaceuticals-inc-announces-extension-of-rights-offering-300405855.html


'/>"/>
SOURCE Provectus Biopharmaceuticals, Inc.
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. How These Drug Makers Stocks are Faring? -- Provectus Biopharma, TherapeuticsMD, Novartis, and Tonix Pharma
2. Drug Makers Stocks on Investors Radar -- Provectus Biopharma, Novartis, TherapeuticsMD, and Tonix Pharma
3. Drug Makers Stocks Under Scanner -- Eli Lilly, Provectus Biopharma, GlaxoSmithKline, and Novartis
4. Provectus Biopharmaceuticals Looks at the Asian Markets: Analyst Coverage by Small Cap Traders
5. Pharma Equities Technical Momentum - Provectus Biopharma, Shire, Impax Labs, Zogenix, and TherapeuticsMD
6. Rodman & Renshaw Initiates Coverage of RegeneRx Biopharmaceuticals, Inc. with Buy Rating
7. Innovate Biopharmaceuticals, Inc. Presenting At Cowen Healthcare Conference Monday, March 7, 2016, And At Future Leaders In The Biotech Industry Friday, March 11, 2016
8. Oxeia Biopharmaceuticals, Inc. Advancing Development Of OXE-103 For The Treatment Of Concussions
9. Global Hyperphosphatemia Drugs Market 2015-2019 with Fresenius Medical Care, Keryx Biopharmaceuticals, Sanofi, Shire & Vifor Pharma Dominating
10. Morgan & Morgan Announces the Investigation of KYTHERA Biopharmaceuticals, Inc. KYTH
11. Harwood Feffer LLP Announces Investigation of Kythera Biopharmaceuticals, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/3/2020)... ... January 03, 2020 , ... Stay on top of current hot topics ... industries. Access to all webinars is free, so be sure to register today to ... Visit http://www.xtalks.com to see our upcoming webinars: , CLINICAL OPERATIONS , January ...
(Date:1/3/2020)... MIAMI (PRWEB) , ... January 03, 2020 , ... American ... the Hood” and the “John Wick” series. While most know him for the movies ... “Behind The Scenes” with Laurence Fishburne. The show explores a vast range of topics ...
(Date:1/1/2020)... , ... January 01, 2020 , ... ... retail franchise, recently donated $25,000 to the Children’s Tumor Foundation through its philanthropic ... Tumor Foundation 2019 Charity Golf Tournament in Orlando, Florida on October 7, 2019. ...
Breaking Medicine Technology:
(Date:1/10/2020)... ... January 10, 2020 , ... NW Women’s Fitness ... non-intimidating environment for all women. In search for a valuable nutrition solution, NW ... members. , For nearly 30 years, Balanced Habits, headquartered in Southern California, ...
(Date:1/8/2020)... ... January 09, 2020 , ... Real ... Webinar, Thursday, Jan. 23, 2020 • 1:30-3:00 p.m. EST, https://www.centerwatch.com/rweanddata ... (RWD) to generate evidence and identify gaps and challenges when conducting trials? The ...
(Date:1/7/2020)... ... January 07, 2020 , ... Destressing the patient payment and billing experience, balancing ... are among the topics to be examined at the HFMA Western Symposium, to be ... executive officer for Healthfuse, a leader in supporting hospitals to more effectively source and ...
(Date:1/7/2020)... (PRWEB) , ... January 06, 2020 , ... After 32 ... unveil its first product: The LumaCare Duo ™. , The first public demonstrations ... Sands Convention Center in Las Vegas, Nevada during CES 2020, the largest consumer electronics ...
(Date:1/7/2020)... , ... January 07, 2020 , ... MMJ International Holdings, ... award for ?Orphan Drug Designation? for its THC and CBD proprietary drug formulation which ... of MMJ’s lead drugs and the company is confident that it will bring much ...
Breaking Medicine News(10 mins):